Hepatitis C virus resistance to the new direct-acting antivirals [PDF]
, 2016 Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella +2 more
core +1 more source
Health Science Reports, 2022 Management of genotype 4 hepatitis C virus (HCV) has shifted to interferon‐free regimens with a high sustained virological response (SVR‐12), especially with NS5B/NS5A inhibitor combinations such as sofosbuvir and ledipasvir (Sof‐Led).
Hala Joharji +13 more
semanticscholar +1 more source
A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]
, 2016 Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed +6 more
core +1 more source
Saudi Journal of Medical and Pharmaceutical Sciences, 2022 Background: The rapid growth of COVID-19 infections may result in second wave of infection and an overwhelmed health care providing systems. Ledipasvir and sofosbuvir can be a good choice for management of COVID-19 patients.
M. Raslan, E. Shehata, S. R, N. Sabri
semanticscholar +1 more source
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. [PDF]
PLoS ONE, 2016 BACKGROUND:Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries.
Guo-Feng Chen +34 more
doaj +1 more source
Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]
, 2017 Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N +15 more
core +1 more source
International journal of pharmaceutical sciences review and research, 2022 A novel and simultaneous stability indicating RP-UPLC method has been developed for quantitative analysis of Ledipasvir and Sofosbuvir in bulk and pharmaceutical dosage forms.
Sandhya Rani Baratam +3 more
semanticscholar +1 more source
Drop-out rate from the liver transplant waiting list due to HCC progression in HCV-infected patients treated with direct acting antivirals. [PDF]
, 2017 BACKGROUND & AIM: concerns about an increased hepatocellular carcinoma (HCC) recurrence rate following directly acting antiviral (DAA) therapy in cirrhotic patients with a prior complete oncological response have been raised. Data regarding the impact of
Angeli, Paolo +16 more
core +1 more source
AA. VV., Los Dominicos y el Nuevo Mundo, Actas del III Congreso Internacional, ed. Deimos, Madrid 1991, 852 pp., 17 x 24. [RECENSIÓN] [PDF]
, 2017 BACKGROUND: Treatment of genotype 1 hepatitis C virus (HCV) infection with combination direct acting anti-virals is associated with very high rates of sustained virological response (SVR).
Afdhal +33 more
core +2 more sources
medRxiv, 2021 Background: COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection.
Mohamed Abdel-Salam Elgohary +24 more
semanticscholar +1 more source